Keloid- Pipeline Insight, 2025

This “Keloid- Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Keloid pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Keloid: Understanding

Keloid: Overview

Keloids are a type of hypertrophic scar that extends beyond the boundaries of the initial skin injury, forming a raised and often irregularly shaped growth. Unlike typical scars, keloids do not regress over time and can continue to expand, sometimes causing physical and cosmetic discomfort. They most commonly occur following skin trauma such as surgical incisions, burns, severe acne, or even minor scratches. Individuals with darker skin tones, such as those of African, Hispanic, and Asian descent, as well as those with a family history of keloids, are more prone to developing these scars. Keloids are characterized by their raised and shiny appearance, often taking on a color that ranges from pink to red to dark brown, depending on the person's skin tone. They are typically firm or rubbery to the touch and can be significantly larger than the original wound. Common symptoms include itchiness, tenderness, and sometimes pain, particularly as the keloid grows. These symptoms can lead to discomfort and functional impairment, especially if the keloid forms over joints or other areas of frequent movement.

The exact cause of keloid formation is not fully understood, but it involves an overproduction of collagen during the wound healing process. Factors contributing to keloid formation include genetic predisposition, skin tension, and the severity of the initial injury. The pathophysiology of keloids involves an imbalance between the synthesis and degradation of collagen, leading to excessive scar tissue formation. This imbalance may be influenced by various cellular and molecular mechanisms, including inflammatory responses and fibroblast activity.

Diagnosis of keloids is primarily clinical, based on the characteristic appearance and history of the lesion. Physicians may conduct a physical examination and review the patient's medical history to identify any contributing factors. In some cases, a skin biopsy may be performed to rule out other conditions such as hypertrophic scars or skin tumors. However, the distinct appearance of keloids usually makes this step unnecessary.

Treatment options for keloids aim to reduce their size, alleviate symptoms, and prevent recurrence. Corticosteroid injections are commonly used to flatten keloids and reduce inflammation. Surgical removal is another option, though it is often combined with other treatments like corticosteroids or radiation therapy to minimize the risk of recurrence. Laser therapy can reduce the size and improve the color of keloids, while cryotherapy involves freezing the keloid to diminish its size. Silicone sheets and gels, applied regularly, can help flatten keloids and reduce redness. In severe cases, pressure therapy or radiation therapy may be employed. Preventive measures include proper wound care, avoiding unnecessary skin trauma, and using silicone gel or sheets early in the wound healing process.

"Keloid- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Keloid pipeline landscape is provided which includes the disease overview and Keloid treatment guidelines. The assessment part of the report embraces, in depth Keloid commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Keloid collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Keloid R&D. The therapies under development are focused on novel approaches to treat/improve Keloid.

Keloid Emerging Drugs Chapters

This segment of the Keloid report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Keloid Emerging Drugs

STP705: Sirnaomics, Inc.

STP705, is a siRNA therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX-2 gene expression. The product candidate has received multiple IND approvals from both the U.S. FDA and Chinese NMPA, including treatments of cholangiocarcinoma, nonmelanoma skin cancer, and hypertrophic scar. A Phase IIa study of STP705 for treatment of squamous cell skin cancer (isSCC) in adult patients demonstrated positive efficacy and safety results, with 76% of all patients (19/25) achieving complete histologically clearance and the two optimal dosing ranges achieving 90% histological clearance of tumor cell in the lesion. No significant or serious adverse events, including no significant cutaneous skin reactions, were reported in the study, and the company was able to define a clear therapeutic window in advance of later stage studies. Currently, the drug is in Phase II stage of its development for the treatment of keloids.

Keloid: Therapeutic Assessment

This segment of the report provides insights about the different Keloid drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Keloid

• There are approx. 5+ key companies which are developing the therapies for Keloid. The companies which have their Keloid drug candidates in the most advanced stage, i.e. phase II include, Sirnaomics, Inc.

Phases

The report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Keloid pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Keloid: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Keloid therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Keloid drugs.

Keloid Report Insights

• Keloid Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Keloid Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Keloid drugs?
• How many Keloid drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Keloid?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Keloid therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Keloid and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sirnaomics
• Yuhan Pharmaceuticals
• Lemonex Inc.,
• CellionBioMed

Key Products

• STP705
• YHC1113
• LEM-S401
• CBM C1

This product will be delivered within 2 business days.